Patients with Parkinson’s Disease (PD) experience REM sleep behavior disorder (RBD) more frequently than healthy controls. RBD is associated with torpid disease evolution. To test the hypothesis that differential genetic signatures might contribute to the torpid disease evolution in PD patients with RBD we compared the rate of genetic mutations in PD patients with or without probable RBD. Patients with a clinical diagnosis of PD in the Parkinson’s Progression Markers Initiative (PPMI) database entered the study. We excluded those with missing data, dementia, psychiatric conditions, or a diagnosis change over the first five years from the initial PD diagnosis. Probable RBD (pRBD) was confirmed by a REM Sleep Behavior Disorder Screening Questionnaire score > 5 points. Logistic regression and Machine Learning (ML) algorithms were used to relate Single Nucleotide Polymorphism (SNPs) in PD-related genes with pRBD. We included 330 PD patients fulfilling all inclusion and exclusion criteria. The final logistic multivariate model revealed that the following SNPs increased the risk of pRBD: GBA_N370S_rs76763715 (OR, 95% CI: 3.38, 1.45–7.93), SNCA_A53T_rs104893877 (8.21, 2.26–36.34), ANK2. CAMK2D_rs78738012 (2.12, 1.08–4.10), and ZNF184_rs9468199 (1.89, 1.08–3.33). Conversely, SNP COQ7. SYT17_rs11343 reduced pRBD risk (0.36, 0.15–0.78). The ML algorithms led to similar results. The predictive models were highly specific (95–99%) but lacked sensitivity (9–39%). We found a distinctive genetic signature for pRBD in PD. The high specificity and low sensitivity of the predictive models suggest that genetic mutations are necessary but not sufficient to develop pRBD in PD. Additional investigations are needed.
10 November 2025 in Frontiers in Molecular Neuroscience
Introduction: Metabolic syndrome (MetS) and Parkinson’s disease (PD) share common pathophysiological and molecular impairments related to high PD incidence in MetS patients. In this study, we searched for independently MetS-associated single-nucleotide polymorphism variants (SNVs) in PD patients and aimed to explain the molecular mechanism involved. Methods: We included 423 PD patients diagnosed by positron emission tomography (PET). A logistic regression model, the chi-squared analysis, and Fisher’s exact test were applied to additive, dominant, and recessive genetic models of data obtained from the Parkinson’s Progression Marker Initiative (PPMI) database. MicroRNA Quantitative trait Loci (MirQTL) analysis and microRNA binding to 5′/3′- untranslated regions (UTR) and conding sequence (CDS) region gene prediction analysis were performed. Expression quantitative trait loci mapping (eQTL) and gene prioritization using weighted co-expression network analysis were used to evaluate the molecular mechanisms. Chromosomal loci that explain variance in expression traits are referred to as eQTLs. Results: The SNV variant rs1803274 was associated with MetS, increased cardiovascular risk, and altered butyrylcholinesterase levels. Eleven microRNAs binding to the BuChe 3′/‘5-UTR and CDS region downregulated its expression. The rs1803274 variant was significantly enriched for neurotransmitter clearance, ghrelin secretion and deacylation, phosphatidylcholine synthesis, glycerophospholipid and lipid metabolism, and synaptic transmission. Forty-six eQTL proteins were associated with the SNV rs1803274. Thirteen of these were prioritized as potential therapeutic targets in a principal component analysis based on node degree parameters, betweenness centrality, and closeness centrality. Conclusion and interpretation: The SNV variant rs1803274 was associated with both MetS and PD and downregulated the expression of BuChe, which is involved in ghrelin hydrolysis. This variant was associated with several MetS-related eQTLs proteins or their components.
Patients with Parkinson’s Disease (PD) experience REM sleep behavior disorder (RBD) more frequently than healthy controls. RBD is associated with torpid disease evolution. To test the hypothesis that differential genetic signatures might contribute to the torpid disease evolution in PD patients with RBD. We compared the rate of genetic mutations in PD patients with or without probable RBD. Patients with a clinical diagnosis of PD in the Parkinson’s Progression Markers Initiative (PPMI) database entered the study. We excluded those with missing data or a diagnosis change over the first five years from the initial PD diagnosis. Probable RBD (pRBD) was confirmed by a REM Sleep Behavior Disorder Screening Questionnaire score >5 points. Logistic regression and Machine Learning (ML) algorithms were used to relate Single Nucleotide Polymorphism (SNPs) in PD-related genes with pRBD. We included 330 PD patients fulfilling all inclusion and exclusion criteria. The final logistic multivariate model revealed that the following SNPs increased the risk of pRBD: GBA_N370S_rs76763715 (OR, 95% CI: 3.38, 1.45-7.93), SNCA_A53T_rs104893877 (8.21, 2.26-36.34), ANK2. CAMK2D_rs78738012 (2.12, 1.08-4.10), and ZNF184_rs9468199 (1.89, 1.08-3.33). Conversely, SNP COQ7. SYT17_rs11343 reduced pRBD risk (0.36, 0.15-0.78). The ML algorithms led to similar results. The predictive models were highly specific (95-99%) but lacked sensitivity (9-39%). We found a distinctive genetic signature for pRBD in PD. The high specificity and low sensitivity of the predictive models suggest that genetic mutations are necessary but not sufficient to develop RBD in PD. Additional investigations are needed.
Background. Metabolic syndrome and Parkinson’s disease share common pathophysiological mechanisms. This study aimed to investigate the metabolic syndrome’s contribution to Parkinson’s disease progression and the genetic traits associated with PD and MetS. Methods. Four hundred and twenty-three newly diagnosed drug-naïve PD patients were analyzed from the Parkinson’s Progression Markers Initiative (PPMI) database. We compared changes in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total score and subscores in Parkinson’s patients with or without metabolic syndrome during the first 5 follow-up years. Then, we compared the frequency of PD-related variants in patients with or without MetS. Results. At baseline, Parkinson’s patients with MetS were typically men (p<0.01), and older (p=0.04), with a higher Hoehn and Yahr score (p=0.01) compared with their counterparts without MetS. They showed higher Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) total scores at baseline and in follow-up years 2, 3, 4, and 5 (all p-values <0.05) as analyzed by the Generalized Estimating Equation model. This was due to an increased motor — MDS-UPDRS Part III — score (p<0.01). MetS was associated with a higher frequency of the ZNF646.KAT8.BCKDK_rs14235 variant and a lower frequency of the variants NUCKS1_rs823118 and CTSB_rs1293298. Conclusions. PD patients with MetS had worse motor symptomatology. Both diseases shared genetic background, including mutations in genes participating in lipids metabolism (BCKDK), autophagy and inflammatory responses (CTSB), and chromatin regulation (NUCKS1).
Some studies show that patients with mutations in the SNCA gene, which codifies for the alpha-synuclein protein, show a particular phenotype. The effects of SNCA Single Nucleotide Polymorphism (SNPs) in recently diagnosed, drug-naïve patients with PD have been less explored. Therefore, we set out to explore the differences in the clinical characteristics of recently diagnosed drug-naïve sporadic PD patients with or without SNCA rs3910105 or rs356181 SNPs. Patients with a clinical diagnosis of PD in the Parkinson’s Progression Markers Initiative (PPMI) database entered the study. We excluded those with missing data, dementia, psychiatric conditions, a diagnosis change over the first five years from the initial PD diagnosis, or with a familial history of PD. Subjects were evaluated with the MDS-Unified PD Rating Scale (MDS-UPDRS), DAT imaging, the Geriatric Depression Scale (GDS), the State-Trait Anxiety Inventory (STAI), the Montreal Cognitive Assessment (MoCA), the SCOPA-AUT for autonomic function, the Epworth Sleepiness Scale (ESS), the RBD Questionnaire, and the University of Pennsylvania Smell Identification Test (UPSIT). We included 308 PD patients fulfilling all inclusion and exclusion criteria. A logistic regression analysis and Machine-Learning models did not disclose any difference between patients either with or without the SNCA rs3910105 SNP or with or without the SNCA rs3910105 polymorphism. Our results suggest that the SNCA polymorphisms rs3910105 and rs356181 have no impact on the phenotype of idiopathic, sporadic, recently diagnosed, drug naïve PD patients.